Modulators of cyclic AMP systems
- PMID: 242200
Modulators of cyclic AMP systems
Abstract
On the basis of the data reported here, one may conclude that although many agents that act in the central nervous system are modulators of the action of cyclic AMP, it is difficult to establish a direct connection between the pharmacologic activity and the levels of cyclic AMP in the brain. This lack of interrelation applies to the benzodiazepines as well as to the pyrazolopyridines. The data for members of the latter group are somewhat frustrating in this regard, since an excellent correlation has been shown to exist between the potency of inhibition of PDE and activity in the antianxiety test. In measurements of steroidogenesis in the isolated adrenal cell, the correlation between activity in vito and the conflict assay is even better. The data presented here and reported elsewhere (Shimizu et al., 1974; Kelly et al., 1974; Mayer and King, 1974; King and Mayer, 1974) provide evidence that agents that act as inhibitors of PDE in cell-free systems exert their influence on cyclic AMP in tissue slices of the brain of guinea pigs by mechanisms that seem not to be related to an effect on PDE. Papaverine, and possibly chlordiazepoxide, may act by releasing agonists that, in turn, stimulate the accumulation of cyclic AMP. This activity is blocked bo other inhibitors of PDE, such as theophyline. Results obtained by the use of platelets are refreshingly clear. Inhibition of aggregation has been shown to occur when the level of cyclic AMP is raised, and a suggestive exists that the most potent inhibitors of platelet PDE are the best potentiators of the action of PGE1 in blocking aggregation. The study utilizing drugs collected from a large number of therapeutic classes makes clear that it is difficult to attribute the mechanism of action for any of the classes studied to modulation of cyclic AMP. An unexpected finding of this study, however, was the fact that pharmacologic agents include an unusually large number of inhibitors of PDE as compared with agents chosen at random. This finding provides a powerful tool for the biochemical pharmacologist who is examining large numbers of compounds in the search for potential drugs.
Similar articles
-
Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.Thromb Haemost. 1984 Oct 31;52(2):205-9. Thromb Haemost. 1984. PMID: 6098048
-
Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.Mol Pharmacol. 1990 May;37(5):671-81. Mol Pharmacol. 1990. PMID: 2160060
-
Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.Br J Pharmacol. 1998 Mar;123(6):1047-54. doi: 10.1038/sj.bjp.0701698. Br J Pharmacol. 1998. PMID: 9559885 Free PMC article.
-
Regulation of cyclic AMP content in normal and malignant brain cells.Adv Cyclic Nucleotide Res. 1975;5:641-58. Adv Cyclic Nucleotide Res. 1975. PMID: 165690 Review.
-
Adaptive responses of brain cyclic AMP-generating systems to alterations in synaptic input.J Cyclic Nucleotide Res. 1976 Sep-Oct;2(5):321-36. J Cyclic Nucleotide Res. 1976. PMID: 12192 Review.
Cited by
-
Further characterization of [3H] flunitrazepam binding sites on cultured mouse astroglia.Neurochem Res. 1985 Jun;10(6):809-17. doi: 10.1007/BF00964538. Neurochem Res. 1985. PMID: 2993938